TY - JOUR PY - 2021// TI - The social and economic cost of sleep disorders JO - Sleep A1 - Streatfeild, Jared A1 - Smith, Jackson A1 - Mansfield, Darren A1 - Pezzullo, Lynne A1 - Hillman, David SP - ePub EP - ePub VL - ePub IS - ePub N2 - STUDY OBJECTIVES: To estimate economic cost of common sleep disorders in Australia for 2019-2020.

METHODS: Costs were estimated for obstructive sleep apnea (OSA), insomnia, and restless legs syndrome (RLS) using prevalence, financial, and nonfinancial data from national databases. These included: (1) financial costs associated with health care, informal care, productivity losses, non-medical accident costs, deadweight loss from taxation/welfare inefficiencies; and (2) nonfinancial costs associated with loss of well-being. They were expressed in US dollars ($).

RESULTS: Estimated overall cost of sleep disorders in Australia in 2019-2020 (population: 25.5 million) was $35.4 billion (OSA $13.1 billion; insomnia $13.3 billion, RLS $9.0 billion). Of this, the financial cost component was $10.0 billion, comprised of: health system costs $0.7 billion; productivity losses $7.7 billion; informal care $0.2 billion; other, mainly non-medical accident costs, $0.4 billion; and deadweight losses $1.0 billion. For moderate to severe OSA syndrome, insomnia unrelated to other conditions and RLS, financial costs represented $16,717, $21,982, and $16,624 per adult with the condition for the year, respectively. The nonfinancial cost was $25.4 billion.

CONCLUSIONS: The economic costs associated with sleep disorders are substantial. The financial component of $10.0 billion is equivalent to 0.73% of Australian gross domestic product. The nonfinancial cost of $25.4 billion represents 3.2% of total Australian burden of disease for the year. Health system costs of these disorders are low relative to those associated with their consequences, suggesting greater expenditure on detection, treatment and prevention is warranted.

Language: en

LA - en SN - 0161-8105 UR - http://dx.doi.org/10.1093/sleep/zsab132 ID - ref1 ER -